On September 24, 2026, a status update was recorded for a clinical trial involving leuprolide. The study, titled "Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer," is registered under identifier NCT03573648. It is a Phase 2 trial evaluating a neoadjuvant endocrine therapy regimen alongside palbociclib and avelumab in patients with estrogen receptor positive breast cancer.
The current status of the trial is listed as active, not recruiting. This means the study is ongoing but is no longer enrolling new participants at this time. No results or outcome data have been reported in this update. The event data does not include information on efficacy, safety findings, or conclusions from the trial.
Leuprolide is an approved compound, and this trial update reflects only its inclusion in this specific research protocol at the noted phase and status. No additional details about trial design changes, participant numbers, or timelines beyond the listed status are provided in the available information.
Readers interested in learning more about leuprolide, including its approved uses and general background, can refer to the compound overview for further context.